Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability

by Ashley M. Hopkins, Andrew Rowland, Michael J. Sorich
Published 2018-09-01

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

by Ashley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, Michael J Sorich
Published 2020-06-01

Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing

by Warit Ruanglertboon, Michael J. Sorich, Ashley M. Hopkins, Andrew Rowland
Published 2021-04-01

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

by Ashley M. Hopkins, Andrew Rowland, Ross A. McKinnon, Michael J. Sorich
Published 2019-08-01

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

by Ashley M. Hopkins, Akash D. Rathod, Andrew Rowland, Ganessan Kichenadasse, Michael J. Sorich
Published 2020-02-01

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

by Ashley M. Hopkins, Anh-Minh Nguyen, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Published 2018-10-01

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

by Ashley M. Hopkins, Adel Shahnam, Sasha Zhang, Chris S. Karapetis, Andrew Rowland, Michael J. Sorich
Published 2019-06-01

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

by Jessica M. Logan, Doug A. Brooks, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
Published 2021-01-01

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combinati...

by Ashley M. Hopkins, Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
Published 2021-07-01

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

by Andrew E. C. Booth, Ashley M. Hopkins, Andrew Rowland, Ganessan Kichenadasse, Justine R. Smith, Michael J. Sorich
Published 2020-07-01

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer

by Ahmad Y. Abuhelwa, Ganessan Kichenadasse, Ross A. McKinnon, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich
Published 2021-04-01

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Tr...

by Ashley M. Hopkins, Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
Published 2021-03-01

Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis

by Natansh D. Modi, Ahmad Y. Abuhelwa, Bradley D. Menz, Ross A. McKinnon, Michael J. Sorich, Ashley M. Hopkins
Published 2021-08-01

Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Su...

by Madelé van Dyk, Asha J. Kapetas, Ashley M. Hopkins, A. David Rodrigues, Manoli Vourvahis, Michael J. Sorich, Andrew Rowland
Published 2019-09-01

Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a multicohor...

by Ahmad Y. Abuhelwa, David J. R. Foster, Arkady Manning-Bennett, Michael J. Sorich, Susanna Proudman, Michael D. Wiese, Ashley M. Hopkins
Published 2021-04-01

Nuances to precision dosing strategies of targeted cancer medicines

by Ashley M. Hopkins, Bradley D. Menz, Michael D. Wiese, Ganessan Kichenadasse, Howard Gurney, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
Published 2020-08-01

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib

by Natansh D. Modi, Ahmad Y. Abuhelwa, Sarah Badaoui, Emily Shaw, Kiran Shankaran, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
Published 2021-08-01

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data

by Natansh D. Modi, Jin Quan Eugene Tan, Andrew Rowland, Bogda Koczwara, Ahmad Y. Abuhelwa, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins
Published 2021-03-01

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data

by Natansh D. Modi, Jin Quan Eugene Tan, Andrew Rowland, Bogda Koczwara, Bogda Koczwara, Ganessan Kichenadasse, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins
Published 2020-07-01